Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSD0922-FU and Osimertinib in NSCLC
NCT07206498Phase 2Recruiting
- Sponsor
- Wayshine Biopharm
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WSD-0922 in non-small cell lung cancer (NSCLC), sponsored by Wayshine Biopharm. Started Oct 2025; status: recruiting.
02
Drugs
WSD-0922
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07206498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206498.